Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Inclusion Criteria: * Patients must have HLA-A2 status known prior to randomization; typing may be obtained through a local laboratory facility or through a reference lab utilized by the initiating institution; if typing is not available through these means, it may be obtained from the University of Pittsburgh * All patients must have disease completely resected with one of the following in order to be eligible: * Completely resected disease * Any locoregional recurrence after prior adjuvant interferon or failure on S008 * Any local recurrence of disease after adequate surgical excision of the original primary * Mucosal melanoma * Stage IV melanoma (cutaneous, ocular, mucosal, or unknown primary) * The following groups of patients may be entered onto this trial only if they are ineligible for S0008 or are, in the opinion of the managing physician, medically unfit to receive standard high-dose interferon: * Any clinically evident satellite or in-transit disease * Stage II disease with gross extracapsular extension * Recurrence in a previously resected nodal basin * Four or more involved lymph nodes or matted lymph nodes * Ulcerated primary melanoma and any involved lymph nodes * NOTE: Patients who are eligible for S0008 will be strongly encouraged to participate in that study in preference to this one * Patients must have been surgically rendered free of disease with negative margins on resected specimens; patients rendered free of disease by non-su…